[Clinical immunology of hepato-splenic bilharziasis].

Field studies on immunity in human schistosomiasis gave evidence for a slow development with age of an acquired resistance to reinfection. Recent results support the idea of a progressive build-up of high levels of protective IgE, and probably IgA, overcoming the initial influence of blocking Ig G4 antibodies. Chemotherapy does not apparently modify the susceptibility to infection. A. Capron's candidate vaccine is now ready for human trials, and represents a promising tool in controlling schistosomiasis morbidity while diminishing the parasite transmission efficiency.
AuthorsP Esterre, P Boisier, V A Ravaolimalala, J Roux
JournalArchives de l'Institut Pasteur de Madagascar (Arch Inst Pasteur Madagascar) Vol. 61 Issue 1 Pg. 28-30 ( 1994) ISSN: 0020-2495 [Print] MADAGASCAR
Vernacular TitleImmunologie clinique de la bilharziose hépato-splénique.
PMID7778947 (Publication Type: English Abstract, Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Antibodies, Helminth
  • Immunoglobulin A
  • Immunoglobulin G
  • Immunoglobulin E
  • Adolescent
  • Adult
  • Animals
  • Antibodies, Helminth (blood)
  • Child
  • Child, Preschool
  • Humans
  • Immunoglobulin A (blood)
  • Immunoglobulin E (blood)
  • Immunoglobulin G (blood)
  • Liver Diseases, Parasitic (drug therapy, immunology, parasitology)
  • Schistosomiasis mansoni (drug therapy, immunology)
  • Splenic Diseases (drug therapy, immunology, parasitology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: